Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
about
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adultsEfficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
P2860
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@ast
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@en
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@nl
type
label
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@ast
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@en
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@nl
prefLabel
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@ast
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@en
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@nl
P2860
P921
P356
P1476
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab
@en
P2093
Daniel Baumgart
P2860
P304
P356
10.2147/DDDT.S50348
P407
P5008
P577
2014-12-17T00:00:00Z